Citation: | ZHANG Bo, ZHU Yulin, XIONG Yuhong, QIN Wengang, CHEN Yana, ZHAO Ya, CHEN Mingwu. Exploration of risk factors for severe Mycoplasma pneumoniae pneumonia in children[J]. Chinese Journal of General Practice, 2024, 22(7): 1094-1097. doi: 10.16766/j.cnki.issn.1674-4152.003574 |
[1] |
ZHANG X, SUN R Y, JIA W Y, et al. Clinical characteristics of lung consolidation with Mycoplasma pneumoniae pneumonia and risk factors for Mycoplasma pneumoniae necrotizing pneumonia in children[J]. Infect Dis Ther, 2024, 13(2): 329-343. doi: 10.1007/s40121-023-00914-x
|
[2] |
LEE E, KIM C H, LEE Y J, et al. Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization in South Korea[J]. BMC Infect Dis, 2020, 20(1): 132. DOI: 132. 10.1186/s12879-020-4810-9.
|
[3] |
LEE K L, LEE C M, YANG T L, et al. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019[J]. J Formos Med Assoc, 2021, 120(1 Pt 1): 281-291.
|
[4] |
SU M, WANG Q, LI D, et al. Prevalence and clinical characteristics of hospitalized children with community-acquired Mycoplasma pneumoniae pneumonia during 2017/2018, Chengde, China[J]. Medicine (Baltimore), 2021, 100(5): e23786. DOI: 10.1097/MD.0000000000023786.
|
[5] |
中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 中国合理用药探索, 2023, 20(3): 16-24. https://www.cnki.com.cn/Article/CJFDTOTAL-XFCR202401015.htm
National Health Commission of the People's Republic of China. Guidelines for Diagnosis and Treatment of Mycoplasma Pneumonae Pneumonia in Children(2023 Edition)[J]. Chinese Journal of Rational Drug Use, 2023, 20(3): 16-24. https://www.cnki.com.cn/Article/CJFDTOTAL-XFCR202401015.htm
|
[6] |
张松林, 熊蕾蕾, 余燕娟, 等. 血清IL-6、RANTES与儿童难治性肺炎支原体肺炎的关系[J]. 中华全科医学, 2023, 21(4): 619-621, 684. doi: 10.16766/j.cnki.issn.1674-4152.002944
ZHANG S L, XIONG L L, YU Y J, et al. Expression of serum IL-6 and RANTES in children with refractory pneumonia caused by mycoplasma pneumoniae and their relationship with prognosis[J]. Chinese Journal of General Practice, 2023, 21(4): 619-621, 684. doi: 10.16766/j.cnki.issn.1674-4152.002944
|
[7] |
李天超, 展效文, 徐亚利, 等. 阿奇霉素联合甲泼尼龙治疗儿童重症肺炎支原体肺炎疗效观察[J]. 新乡医学院学报, 2023, 40(6): 543-547. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX202306009.htm
LI T C, ZHAN X W, XU Y L, et al. Effect of azithromycin combined with methylprednisolone in the treatment of severe Mycoplasma pneumoniae pneumonia in children[J]. Journal of Xinxiang Medical University, 2023, 40(6): 543-547. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX202306009.htm
|
[8] |
BIAGI C, CAVALLO A, ROCCA A, et al. Pulmonary and extrapulmonary manifestations in hospitalized children with Mycoplasma pneumoniae infection[J]. Microorganisms, 2021, 9(12): 2553. DOI: 10.3390/microorganisms9122553.
|
[9] |
FAN F, LV J, YANG Q Y, et al. Clinical characteristics and serum inflammatory markers of community-acquired Mycoplasma pneumoniae in children[J]. Clin Respir J, 2023, 17(7): 607-617. doi: 10.1111/crj.13620
|
[10] |
ITO A, ISHIDA T. Diagnostic markers for community-acquired pneumonia[J]. Ann Transl Med, 2020, 8(9): 609. DOI: 10.21037/atm.2020.02.182.
|
[11] |
MEYER SAUTEUR P M, KRAUTTER S, AMBROGGIO L, et al. Improved diagnostics help to identify clinical features and biomarkers that predict Mycoplasma pneumoniae community-acquired pneumonia in children[J]. Clin Infect Dis, 2020, 71(7): 1645-1654. doi: 10.1093/cid/ciz1059
|
[12] |
LI Y T, ZHANG J, WANG M Z, et al. Changes in coagulation markers in children with Mycoplasma pneumoniae pneumonia and their predictive value for mycoplasma severity[J]. Ital J Pediatr, 2023, 49(1): 143. DOI: 10.1186/s13052-023-01545-1.
|
[13] |
ZHENG Y, HUA L L, ZHAO Q N, et al. The level of D-Dimer is positively correlated with the severity of Mycoplasma pneumoniae pneumonia in children[J]. Front Cell Infect Microbiol, 2021, 11: 687391. DOI: 10.3389/fcimb.2021.687391.
|
[14] |
MILENKOVIC M, HADZIBEGOVIC A, KOVAC M, et al. D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict In-Hospital mortality in patients with COVID-19 pneumonia[J]. Oxid Med Cell Longev, 2022, 2022: 8997709. DOI: 10.1155/2022/8997709.
|
[15] |
QIU J, GE J, CAO L. D-dimer: the risk factor of children's severe Mycoplasma pneumoniae pneumonia[J]. Front Pediatr, 2022, 10: 828437. DOI: 10.3389/fped.2022.828437.
|
[16] |
ZHENG B Y, ZHAO J, CAO L. The clinical characteristics and risk factors for necrotizing pneumonia caused by Mycoplasma pneumoniae in children[J]. BMC Infect Dis, 2020, 20(1): 391. DOI: 391. 10.1186/s12879-020-05110-7.
|
[17] |
GUPTA G S. The lactate and the lactate dehydrogenase in inflammatory diseases and major risk factors in COVID-19 patients[J]. Inflammation, 2022, 45(6): 2091-2123. doi: 10.1007/s10753-022-01680-7
|
[18] |
LEE E, LEE Y Y. Predictive factors of the responses to treatment of Mycoplasma pneumoniae pneumonia[J]. J Clin Med, 2021, 10(6): 1154. DOI: 10.3390/jcm10061154.
|